WAIKOLOA, Hawaii — In this video from Hawaiian Eye 2022, Bobak Azamien, MD, PhD, president and CEO of Tarsus Pharmaceuticals, discussed the company’s plans to move TP-03 toward FDA approval.
“We have a number of things happening this year,” he said. “First and foremost, our pivotal trial, SATURN-2 phase 3 trial for TP-03, for the treatment of Demodex blepharitis. That will be out early this year, and that will be followed by our NDA submission for Demodex blepharitis.”